详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

IGFBP3 Enhances Treatment Outcome and Predicts Favorable Prognosis in ABC-DLBCL

文献详情

资源类型：

Pubmed体系：

作者：

单位： [1]Department of Clinical Laboratory, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. [2]Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China. [3]Department of Clinical Laboratory, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China. [4]Center for Clinical Laboratory, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.

出处：

DOI：

ISSN：

摘要：

Chemoresistance is a key obstacle in the clinical treatment and management of activated B cell-like diffuse large B-cell lymphoma (ABC-DLBCL), which leads to the poor prognosis of patients. Exploring novel biomarkers to early warn drug resistance and ameliorate the patients' outcome in ABC-DLBCL is urgent and crucial. Previously, we found that insulin-like growth factor-binding protein 3 (IGFBP3) was remarkably associated with immunochemotherapy treatment response through microarray screening. Based on a retrospective cohort (n = 160) and a GEO cohort (n = 292), here we determined the positive expression rate of IGFBP3 and analyzed the role of IGFBP3 in treatment response and prognostics in ABC-DLBCL. The results demonstrated that the complete response (CR) rate of R-CHOP treatment was higher in ABC-DLBCL with IGFBP3 positive expression than those with IGFBP3 negative expression (42.0% vs 26.4%), and IGFBP3 positive expression in ABC-DLBCL was significantly correlated with enhanced therapeutic response (P = 0.037). High level of IGFBP3 was negatively correlated with tumorigenesis and development and predicted favorable survival time in ABC-DLBCL. In conclusion, IGFBP3 may be utilized as a promising biomarker for prognosis evaluation and a potential therapy target in ABC-DLBCL patients.Copyright © 2023 Han-Bing Li et al.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 3 区医学

小类 | 4 区肿瘤学

最新[2025]版：

无

JCR分区：

出版当年[2021]版：

Q2 ONCOLOGY

最新[2023]版：

无

影响因子： 最新[2023版] 0 最新五年平均[2021-2025] 0 出版当年[2021版] 4.501 出版当年五年平均[2017-2021] 4.463 出版前一年[2020版] 4.375

第一作者：

第一作者单位： [1]Department of Clinical Laboratory, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：